Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 27:14:14-19.
doi: 10.1016/j.ijcha.2016.11.002. eCollection 2017 Mar.

Dipyridamole-induced adverse effects in myocardial perfusion scans: Dynamic evaluation

Sin-Di Lee  1 , Wei-Chun Huang  2   3   4 , Nan-Jing Peng  1   2 , Chin Hu  1
Affiliations

Dipyridamole-induced adverse effects in myocardial perfusion scans: Dynamic evaluation

Sin-Di Lee et al. Int J Cardiol Heart Vasc. .

Abstract

Aim and background: Dipyridamole-induced stress myocardial perfusion scans (MPS) has been widely used for management of coronary artery disease. The adverse effects of dipyridamole and other stress agents have been evaluated. The aim of this research is to confirm the dynamic data on dipyridamole side effects during MPS.

Methods: We collected data of 183 patients who underwent dipyridamole-induced stress MPS by retrospectively reviewing their clinical records, which included the severity of dipyridamole side effects in 3 min, 10 min, and 20 min after infusion. The incidence and severity at all three points, including the effect of age and gender, were obtained.

Results: Adverse effects occurred in 96 patients (69.6%). The most frequent symptoms were dizziness (42.8%), chest tightness (24.6%), abdominal pain (18.1%), and headache (15.2%). Most symptoms were Grade 1 to 2, according to the grading system for common terminology criteria. The median duration of symptom persistence was 36 min, not significantly different among age and gender.

Conclusion: This study demonstrates that the adverse effects of dipyridamole were generally minimal and its duration was acceptable for clinical usage.

Keywords: Adverse effects; Dipyridamole; Myocardial perfusion scan.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Severity of adverse effects after dipyridamole infusion at 3 different points. Grading is based on CTCAE v4.0.
Fig. 2
Fig. 2
For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier curve.
Fig. 3
Fig. 3
For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier curve. There is no difference between genders.
Fig. 4
Fig. 4
For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier curve. There is no difference between genders.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. 2015. 2014 Statistics of causes of death, Ministry of Health and Welfare of Republic of China.
    1. Fihn S.D., Gardin J.M., Abrams J., Berra K., Blankenship J.C., Dallas A.P., Douglas P.S., Foody J.M., Gerber T.C., Hinderliter A.L., King S.B., Kligfield P.D., Krumholz H.M., Kwong R.Y.K., Lim M.J., Linderbaum J.A., Mack M.J., Munger M.A., Prager R.L., Sabik J.F., Shaw L.J., Sikkema J.D., Smith C.R., Smith S.C., Spertus J.A., Williams S.V. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2012;60:e44–e164. - PubMed
    1. Hesse B., Tägil K., Cuocolo A., Anagnostopoulos C., Bardiés M., Bax J., Bengel F., Busemann Sokole E., Davies G., Dondi M., Edenbrandt L., Franken P., Kjaer A., Knuuti J., Lassmann M., Ljungberg M., Marcassa C., Marie P.Y., McKiddie F., OConnor M., Prvulovich E., Underwood R., Eck-Smit B. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur. J. Nucl. Med. Mol. Imaging. 2005;32:855–897. - PubMed
    1. Hendel R.C., Berman D.S., Di Carli M.F., Heidenreich P.A., Henkin R.E., Pellikka P.A., Pohost G.M., Williams K.A. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Nuclear Cardiology, American College of Radiology, American Heart Association, American Society of Echocardiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, Society of Nuclear Medicine, ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J. Am. Coll. Cardiol. 2009;53:2201–2229. - PubMed
    1. Dubrey S.W., Bomanji J.B., Noble M.I., Jewkes R.F. Safety of intravenous dipyridamole thallium myocardial perfusion imaging: experience in 435 patients. Nucl. Med. Commun. 1993;14:303–309. - PubMed

LinkOut - more resources